We are live on ! Find out more
APRE icon

Aprea Therapeutics
APRE

20 hedge funds and large institutions have $4.44M invested in Aprea Therapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

21% more capital invested

Capital invested by funds: $3.66M → $4.44M (+$776K)

1.78% more ownership

Funds ownership: 23.46% → 25.24% (+1.8%)

5% less funds holding

Funds holding: 21 → 20 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
20
Holders Change
-1
Holders Change %
-4.76%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
6
Reduced
3
Closed
2
Calls
$621K
Puts
–
Net Calls
+$621K
Net Calls Change
+$67K

Top Buyers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$179K
2
Morgan Stanley
Morgan Stanley
New York
+$81.4K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$30.1K
4
Wells Fargo
Wells Fargo
California
+$8
5
Bank of America
Bank of America
North Carolina
+$4

Top Sellers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
-$9.64K
2
TRCT
Tower Research Capital (TRC)
New York
-$4.91K
3
BlackRock
BlackRock
New York
-$2.97K
4
BOC
Bull Oak Capital
California
-$162
5
Creative Planning
Creative Planning
Kansas
-$105
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
AIGH Capital Management
Maryland
$1.64M – – –
SCM
2
Sio Capital Management
New York
$1.32M – – –
WVP
3
Worth Venture Partners
New Jersey
$410K – – –
Walleye Capital
4
Walleye Capital
New York
$376K -$9.64K -2,356 -3%
Royal Bank of Canada
5
Royal Bank of Canada
Ontario, Canada
$207K +$179K +43,708 +13,788%
Vanguard Group
6
Vanguard Group
Pennsylvania
$163K +$30.1K +7,347 +27%
Morgan Stanley
7
Morgan Stanley
New York
$162K +$81.4K +19,874 +136%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$82.2K – – –
BlackRock
9
BlackRock
New York
$40K -$2.97K -726 -8%
Bank of America
10
Bank of America
North Carolina
$15.3K +$4 +1 +0%
Group One Trading
11
Group One Trading
Illinois
$10.2K – – –
PNC Financial Services Group
12
PNC Financial Services Group
Pennsylvania
$4.7K – – –
MLA
13
MB, Levis & Associates
Pennsylvania
$3.79K – – –
TRCT
14
Tower Research Capital (TRC)
New York
$2.58K -$4.91K -1,199 -69%
Wells Fargo
15
Wells Fargo
California
$1.28K +$8 +2 +0.7%
Osaic Holdings
16
Osaic Holdings
Arizona
$940 – – –
W
17
WealthCollab
Washington
$743 +$647 +158 New
PGAM
18
Princeton Global Asset Management
New Jersey
$470 – – –
JP Morgan Chase
19
JP Morgan Chase
New York
$24 +$4 +1 +25%
UBS Group
20
UBS Group
Switzerland
$14 – – –
BOC
21
Bull Oak Capital
California
– -$162 -39 Closed
Creative Planning
22
Creative Planning
Kansas
– -$105 -25 Closed

APRE Hedge Fund Activity: Q4 2023 in Review

20 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q4 2023, worth a combined $4.44M — up 21% from $3.66M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of APRE and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 6 added.

The largest buyer was Royal Bank of Canada, adding an estimated $179K. The largest seller was Walleye Capital, cutting an estimated $9.64K.

  • 20 institutional investors held Aprea Therapeutics (APRE) as of Q4 2023, down from 21 in Q3 2023.
  • Funds reported $4.44M of Aprea Therapeutics stock for Q4 2023, up 21% quarter-over-quarter.
  • 1 fund opened new Aprea Therapeutics positions in Q4 2023 and 2 closed out, a net change of -1 holder.
  • The largest Aprea Therapeutics buyer in Q4 2023 was Royal Bank of Canada, an estimated $179K added.
  • The largest Aprea Therapeutics seller in Q4 2023 was Walleye Capital, an estimated $9.64K sold.

Based on aggregated 13F filings for Q4 2023.